0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TYRO3

TYRO3

Brief Information

Name:TYRO3 protein tyrosine kinase
Target Synonym:Tyrosine-Protein Kinase RSE,BYK,Tyrosine-Protein Kinase Receptor TYRO3,Tyrosine-Protein Kinase BYK,Etk-2,Rek,DTK,SKY,TIF,Brt,RSE,Tyrosine-protein kinase DTK,Tyrosine-protein kinase SKY,TYRO3,Tyrosine-protein kinase TIF,TYRO3 Protein Tyrosine Kinase
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TY3-H5251 Human Human TYRO3 / Dtk Protein, Fc Tag
TY3-H5251-structure
TY3-H5251-sds

Synonym Name

TYRO3,BYK,DTK,RSE,SKY,TIF

Background

Tyrosine-protein kinase receptor TYRO3 is also known as Tyrosine-protein kinase BYK, DTK, RSE, SKY, TIF, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. TYRO3 regulates many physiological processes including cell survival, migration and differentiation. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 interacts (via N-terminus) with extracellular ligands TULP1 and GAS6 By similarity and also interacts with PIK3R1, this interaction increases PI3-kinase activity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate BMS-907351; XL-184 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Solid tumours; Pain; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RXDX-106 RXDX-106 Phase 1 Clinical Teva, Daiichi Sankyo Co Ltd Solid tumours; Neoplasms Details
Insulin tregopil (Biocon) HIM-2; IN-105; NIN-058; GW-843362 Phase 2 Clinical Biocon Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 Details
Insulin icodec 148-0287-A; Insulin-287; LAI-287; Long-acting basal insulin analogue; Long-acting-insulin-287; NN-1436; NN-1956; NNC-0148-0000-0287; NNC0148-0287 C; OI-287GT Phase 3 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus Details

This web search service is supported by Google Inc.

totop